Former Executive Vice President of Research & Development, Chief Scientific Officer and Director · Monopar Therapeutics (MNPR)

Andrew Mazar

A named executive officer of Monopar Therapeutics in every fiscal year CompBrief holds from FY2018 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$899,295

Salary $455,500Stock awards $174,997

FY2020: $872,571

2nd of 3 named executive officers at Monopar Therapeutics by FY2021 total.

3 named officers on file for Monopar Therapeutics, FY2021

Andrew Mazar’s pay file — $29

  • 4 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Monopar Therapeutics’s whole pay program stands against its peers

  • Monopar Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MNPR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2022 (DEF 14A).

Free

Get Andrew Mazar’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Andrew Mazar compensation by year

Monopar Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Monopar Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021
Salary$350,000$360,500$438,008$455,500
Bonus$5,600$50,000$0$0
Stock awards$0$0$100,182$174,997
Option awards$591,592$0$293,381$174,999
Non-equity incentive$0$0$41,000$93,800
Pension and deferred compensation$0$0$0$0
All other$55,000$55,000$0$0
Total$1,002,192$465,500$872,571$899,295

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Monopar Therapeutics DEF 14A filed April 29, 2022, accession 0001654954-22-005658, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Monopar Therapeutics filed document, accession 0001654954-22-005658. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2022.

$1.0M
$466K
$873K
$899K
FY18
FY19
FY20
FY21
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU88,792$285,022—
Option27,058—$6.81
Option16,096—$14.35
Option31,602—$6.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Monopar Therapeutics's FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Monopar Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Chandler RobinsonMD, Chief Executive Officer and Director$1,428,588
Andrew Mazar · this pageFormer Executive Vice President of Research & Development, Chief Scientific Officer and Director$899,295
Kim TsuchimotoChief Financial Officer$593,880

The full Monopar Therapeutics compensation record

free company brief

This page is one person within Monopar Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Monopar Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Andrew Mazar's compensation dossier · One-time report. No refunds.